New, True & Poo. Faculty/Presenter Disclosure

Size: px
Start display at page:

Download "New, True & Poo. Faculty/Presenter Disclosure"

Transcription

1 New, True & Poo Unpleasant Truths Comforting Lies Tina, Mike K, Adrienne, Mike A, Evidence & CPD Program, Alberta College of Family Physicians Department of Family Medicine, University of Alberta Faculty/Presenter Disclosure Faculty/Presenter: Mike Allan, Mike Kolber & Tina Korownyk Where we get Personal $: U of A, Alberta Health Faculty/Presenter: Adrienne Lindblad (ACFP salary) Where we get Grant/ Program $: Alberta College of Family Physicians, Other Colleges of Family Physicians, Toward Optimized Practice, Other non profit organizer Relationships with commercial interests: Grants/Research Support: Not applicable Speakers Bureau/Honoraria: Not applicable Consulting Fees: Not applicable Other: None 1

2 What s New What s True What s Poo Quirks Survey: 203 pts & 151 docs regarding good care Choose Wisely needs to look at more than docs. Category Patients Doctors Tension Headache, no CT 36% 82% Explain risk of CT 51% 64% Second Opinion for CT 30% 5% URTI, no antibiotic 66% 95% Explain CPG against Abx 81% 95% Primary Care Workload : 101,818,352 visits (2007 vs 14) Annual visits per patients 4.7 to 5.2 Telephone doubled and 5% increase in office (which 90% of contacts) Time per visit was 8.65 minutes and now is 9.22 minutes. Overall: workload increased 16% in 7 years. JAMA Intern Med Aug 1;176(8): Lancet Jun 4;387(10035):

3 MK Medication Expiratory Dates Expiration dates: ~1 5 years post production California Pharmacy found 8 meds (15 compounds) expired for years. Analyzed 14 compounds: 1 pain, sedative 3 tablets tested x 3Xs 12/14 tested compounds: >90% labeled potency US Military SLEP program: 88% of 122 meds tested retained potency 1year (average extension 6 years) Exceptions: Nitroglycerin, insulins, some Abx Bottom Line: keep using your (slightly) expired meds ARCH INTERN MED 2012; 172 (21), DrugSafety Information forpatientsandproviders AL Vitamin D, Big doses and Falls RCT: 200 Swiss pts, mean 78yrs, previous fall, 67% female, & 58% had Vitamin D <50 nmol/l, x1yr Oral: 24,000 IU, 60,000 IU or 24,000 IU + 300μg of calcifediol (per month) Outcome: Vitamin rose 30, 45 and 65 nmol/l High Dose: no improved Physical function tests Fallers ( 1 fall): 48% low dose, 66 67% high dose, NNH 6 Mean # of falls: 0.94, 1.47 and 1.24 (p=0.09) Bottom Line: High dose vitamin D is potentially dangerous in seniors. (Third study to show) Bischoff Ferrari. JAMA Intern Med. 2016;176(2):. doi: /jamainternmed

4 TK Duration of Antibiotics RCT 312 hospitalized for pneumonia. All 5 d of Abx. If temp 37.8 x 48hours and 1 pneumonia instability Sx Outcome: median Abx use was 5 vs 10 d. Symptom Resolution day 10: 56% vs 49%. Similar later. Readmission by day 30 1% vs 7%. No diff mean days to improvement (12 d), X ray resolution, length hospital stay & mortality. Bottom Line: Antibiotic duration can be guided by symptoms (not arbitrary durations). Uranga. JAMA Intern Med doi: /jamainternmed TFP update 4

5 MK Medication for Passing Renal Stones TFP #18. help pass stones by 28 days (NNT 4) Largest RCT, 1167 pts, ureteric stone <10 mm Nifedipine (SR) 30mg, tamsulosin 0.4mg or placebo OD x4 wks Outcome: No difference between groups All the same: Spontaneous stone passage (~80%), Time to stone passage, analgesic use, or self reported health status In stones >5 mm: 71% tamsulosin vs 61% placebo (p=0.13). Stopping for adverse events: nifedipine (NNH=10) & tamsulosin (NNH=25). Bottom Line: Best evidence indicates that nifedipine does not help pass renal stones. Furthermore, there is real doubt if alpha blockers like tamsulosin provide any benefit (except perhaps in stones >5mm). TFP #18 (1 st : January 18, 2010). Lancet 2015;386: Health Technol Assess 2015;19(63). SPRINT: BP targets (TFP 37) RCT: 9361 pts, target <140 vs <120. Age 50, BP 140 Higher risk pts: 17% CVD, mean Framingham 20%, Stopped early. Outcome: 121 vs 136 mmhg at 3.26 yrs, meds 2.8 vs 1.8 CVD: 5.2% vs 6.8%, HR 0.75 ( ), NNT 61 Death: 3.3% vs 4.5%, HR 0.73 ( ), NNT 90, Harms: Hypotension 3.4% vs 2%, syncope 3.5% vs 2.4%, electrolyte 3.8% vs 2.8%, Acute kidney injury/failure 4.4% vs 2.6% Important Caveats Subgroups same: Age 75 (2636 pts) & Others (Gender, Race, CKD) Exclusion: Ejection fraction <35%, Diabetes, Past stroke, egfr<20, standing BP at 1 min <110 Bottom Line: Strong evidence to lower BP targets in higher risk patients (not diabetics this time). No clear that helpful for kidneys? N Engl J Med 2015; 373:

6 The Pharmaceutical Graveyard H o p e AL Changing Dietary Fats to Live Longer RCT: Minnesota Coronary Experiment (MCE) , follow up 3 yrs, 2355 pts, age 52, 53% male, vegetable oil (n 6 linoleic acid via corn, replace saturated fat Outcome: Cholesterol down 14% (0.8 mmol/l) vs 1% Recovered survival analysis: No effect (if anything, trend to harm, particularly age 65) Partial data with autopsy (on MI): 41% diet vs 22% control Meta analysis (5 RCTs, 10,808 pts): of actual diet (not advice) CHD death = hazard ratio 1.13 (0.83 to 1.54) Bottom Line: No RCT support dietary modification of fats intake to improve CVD or death. Ramsden. BMJ 2016;353:i1246 6

7 COPD: LABA + LAMA vs LABA +steroid RCT: 3362 pts (age 65, 76% male, FEV 44%) x 1 yr. Indacaterol (110 μg) + glycopyrronium (50 μg) OD vs salmeterol (50 μg) + fluticasone (500 μg) Outcome: Rate of mod severe exacerbation: 0.98 vs 1.19, rate ratio 0.83 ( ) Time to mod severe exacerbation: 127d vs 87d, HR 0.78 ( ) SGRQ ~1.3 better with LABA+LAMA (0 100, 4 MCID) pneumonia was 3.2% vs 4.8% ss Bottom Line: LABA + LAMA seems to be slightly better combination than LABA + steroids. N Engl J Med Jun 9;374(23): TK Hydrating Kids: Electrolyte solution? RCT 647 kids (mean 28 months, 51% male, 68% score 0 and 25% score 1 2 out of 8), daily f/u ½ strength apple juice vs apple flavored, sweetened Pediatric Electrolyte, each 2L given 5mL q2 5 minutes Outcomes: Tx failure 17% vs 25%, NNT ~12. Mostly less return to care, hospitalization & IV rehydration Rehydration equal if <24 months, 24 months ½ AJ better Bottom line: For kids with minimal dehydration, ½ strength AJ (or preferred fluids) as good as electrolyte solution. JAMA. 2016;315(18):

8 RESEARCH MK 5 Second Rule Dropped foods: 4 inoculated surfaces (steel, tile, wood, carpet), measured bacteria transfer Contact time, food and surface type effected all bacteria transfer (watermelon, carpet ) Coliform count on different household sites: Surface Coliforms / inch 2 Toilet Seat 0.68 Kitchen Floor 2.75 Fridge Handle or Kitchen counter ~6 Toilet flush handle 34 Kitchen rag or sponge 20,000,000 Bottom Line: Wash your rags! Appl. Environ. Microbiol. doi: /aem Carroll A, New York Times Oct 12, 2016, Journal of Applied Microbiology 1998, 85: 819 8

9 Incompetent & unaware: Linked by Necessity 4 studies: humour, logic, grammar/reflection) & logic/training (Done university students) Outcomes: Bottom quartile estimated their ability ~65 percentile (above average). Showing others work only did not help bottom quartile self assess. Only training helped self assess. Bottom Line: If you are bad at something, you don t know it. Ignorance more frequently begets confidence than does knowledge J Pers Soc Psychol Dec;77(6): TK 9 studies (but discussed many others) Testing: hand grip strength, mental health, blood samples, etc If sex is within 2 hours before competition High quality, randomized controlled studies are urgently needed. 9

10 More Illumination to Follow 10

New, True & Poo. Faculty/Presenter Disclosure

New, True & Poo. Faculty/Presenter Disclosure New, True & Poo Unpleasant Truths Comforting Lies Tina, Mike K, Adrienne, Mike A, Evidence & CPD Program, Alberta College of Family Physicians Department of Family Medicine, University of Alberta Faculty/Presenter

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

What s New, What s True, and What s Poo Part 1

What s New, What s True, and What s Poo Part 1 What s New, What s True, and What s Poo Part 1 Tina Korowynk and Mike Kolber PEER Group What s New? What s True? What s Poo? 1 Anti-Depressants Meta-Analysis (Network): 522 RCTs (116477 pts) Mean duration

More information

Faculty/Presenter Disclosures

Faculty/Presenter Disclosures What s New, What s True, and What s Poo FMF November 2018 Tina Korownyk, Adrienne Lindblad, Mike Allan, Mike Kolber PEER Team, U of A & CFPC Faculty/Presenter Disclosures Faculty: Michael Kolber, Tina

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

Managing Back Pain. Faculty/Presenter Disclosure

Managing Back Pain. Faculty/Presenter Disclosure Managing Back Pain G. Michael Allan Evidence & CPD Program, Alberta College of Family Physicians Professor, Dept Family Med, U of A. Faculty/Presenter Disclosure Faculty/Presenter: G. Michael Allan Relationships

More information

Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives

Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Bess Dawson-Hughes, MD Disclosures: Amgen, DSM, Nestle, Opko, Pfizer, Roche, Tricida Interrelationships of muscle

More information

Treating Hypertension in 2018: What Makes the Most Sense Today?

Treating Hypertension in 2018: What Makes the Most Sense Today? Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or

More information

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College

More information

Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina) S. Korownyk EDMONTON AB MEDICAL CANNABANOIDS IN PRIMARY CARE

Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina) S. Korownyk EDMONTON AB MEDICAL CANNABANOIDS IN PRIMARY CARE Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 262 Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina)

More information

5 Things to Know About Irritable Bowel Syndrome

5 Things to Know About Irritable Bowel Syndrome 5 Things to Know About Irritable Bowel Syndrome Mike Kolber MD, CCFP, MSc PEIP 2017 Faculty/Presenter Disclosure Presenter: Mike Kolber Relationships that may introduce potential bias and/or conflict of

More information

Osteoporosis Update DR. SYLVIE OUELLETTE RHEUMATOLOGIST

Osteoporosis Update DR. SYLVIE OUELLETTE RHEUMATOLOGIST Osteoporosis Update DR. SYLVIE OUELLETTE RHEUMATOLOGIST Disclosures! Speaker programs! AbbVie, Amgen! Research! Amgen, Novartis! Education/ conference support! Amgen, Roche! Advisory Boards! AbbVie, Amgen,

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

Opioids: The Cause of, and Solution

Opioids: The Cause of, and Solution Opioids: The Cause of, and Solution to, All Things Pain Tina Korownyk & Jessica Kirkwood Faculty/Presenter Disclosure Presenter: Tina Korownyk Relationships that may introduce potential bias and/or conflict

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

Pulmonary Year in Review

Pulmonary Year in Review Pulmonary Year in Review Rachel Givelber, MD University of Pittsburgh SOM Pulmonary, Allergy, Critical Care and Sleep Medicine Rachel Givelber, MD Assistant Professor of Medicine PACCM, UPSOM Disclosures

More information

Dr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective

Dr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland

More information

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP

More information

Three better than 1 or 2?

Three better than 1 or 2? Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic

More information

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST

More information

Faculty/Presenter Disclosure

Faculty/Presenter Disclosure Weight loss & Obesity WHAT S NEW & EXCITING? Tina Korownyk Dept of Family Medicine, UofA Faculty/Presenter Disclosure Faculty/Presenter: Tina Korownyk Relationships with commercial interests: None 1 Drowning

More information

The New Hypertension Guidelines

The New Hypertension Guidelines The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Hypertension and the SPRINT Trial: Is Lower Better

Hypertension and the SPRINT Trial: Is Lower Better Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,

More information

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of

More information

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT) 09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP

More information

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the

More information

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Update in Hypertension

Update in Hypertension Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded

More information

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014 HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted

More information

Blood pressure treatment target in diabetes. Should it be <130 mmhg?

Blood pressure treatment target in diabetes. Should it be <130 mmhg? Blood pressure treatment target in diabetes Should it be

More information

2016 Update in Geriatrics Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Oregon Geriatrics Society October 7, 2016

2016 Update in Geriatrics Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Oregon Geriatrics Society October 7, 2016 2016 Update in Geriatrics Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Oregon Geriatrics Society October 7, 2016 I have no conflicts of interest Photos thanks to Google images This year

More information

The Evidence for Populationwide Reduction in Sodium Intake: Why All the Fuss?

The Evidence for Populationwide Reduction in Sodium Intake: Why All the Fuss? The Evidence for Populationwide Reduction in Sodium Intake: Why All the Fuss? CIA-Harvard Menus of Change National Leadership Summit June 10, 2014 Cambridge, MA General Session IV Lawrence J Appel, MD,

More information

Controversies in Preventative Cardiology

Controversies in Preventative Cardiology Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence

More information

Managing Hypertension in 2016

Managing Hypertension in 2016 Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Nutraceuticals and Cardiovascular Disease: Are we fishing?

Nutraceuticals and Cardiovascular Disease: Are we fishing? Nutraceuticals and Cardiovascular Disease: Are we fishing? ACC Rockies 2013 March 20,2013 Sheri L. Koshman BScPharm, PharmD, ACPR Assistant Professor, Division of Cardiology, University of Alberta sheri.koshman@ualberta.ca

More information

Established Risk Factors for Coronary Heart Disease (CHD)

Established Risk Factors for Coronary Heart Disease (CHD) Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Heart Disease Genesis

Heart Disease Genesis Heart Disease Genesis The Ultimate Lecture on CAD origins Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Managing Hypertension in 2018

Managing Hypertension in 2018 MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School

More information

Faculty/Presenter Disclosure

Faculty/Presenter Disclosure CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO

More information

NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N

NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N OBJECTIVES List controversial points from the current Dietary Guidelines for Americans (DGA). Recognize the policy

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

What s the evidence, why do guidelines differ, and what should the GP do?

What s the evidence, why do guidelines differ, and what should the GP do? What s the evidence, why do guidelines differ, and what should the GP do? Richard McManus Barcelona 2018 Overview What is hypertension? How should blood pressure be measured/diagnosed? What should we be

More information

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD. Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of

More information

Airway Vista Background

Airway Vista Background Airway Vista 2013 Chronic Obstructive Airway Diseases Symposium Asan Medical Center, Seoul, South Korea When Should Macrolide Antibiotics be Prescribed to Prevent COPD Exacerbations in Usual Clinical Practice?

More information

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:

More information

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies

More information

Hypertension: 2016 Clinical Update

Hypertension: 2016 Clinical Update PHASE Safety Net Community Benefit Hypertension: 2016 Clinical Update Presented by: Joseph Young, MD Hypertension Clinical Lead Kaiser Permanente Northern California October 6, 2016 Dr. Joseph Young Hypertension

More information

Online clinical pathway for chronic kidney disease (CKD) in primary care. February 27, 2015 Dr. Kerry McBrien University of Calgary

Online clinical pathway for chronic kidney disease (CKD) in primary care. February 27, 2015 Dr. Kerry McBrien University of Calgary Online clinical pathway for chronic kidney disease (CKD) in primary care February 27, 2015 Dr. Kerry McBrien University of Calgary FACULTY/PRESENTER DISCLOSURE Faculty: Kerry McBrien Relationships with

More information

No conflicts of interest or disclosures

No conflicts of interest or disclosures Egg and Dairy Consumption: Impact on CVD Risk No conflicts of interest or disclosures Vasanti Malik, ScD Research Scientist Department of Nutrition Harvard School of Public Health Cardiovascular Disease

More information

Glucose Control and Prevention of Cardiovascular Disease

Glucose Control and Prevention of Cardiovascular Disease Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Pharmacotherapy for COPD

Pharmacotherapy for COPD 10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in

More information

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved. Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights

More information

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &

More information

Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle. JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège

Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle. JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège Disclosure No competing interest to declare about this

More information

Blood Pressure Treatment Goals

Blood Pressure Treatment Goals Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC

UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC DISCLOSURES: I have no conflict-of-interest disclosures UPDATES: THE STRUGGLE

More information

HYPERTENSION: UPDATE 2018

HYPERTENSION: UPDATE 2018 HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million

More information

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JAMA. 2011;305(24): Nora A. Kalagi, MSc JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for

More information

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern

More information

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients. Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded

More information

Vitamin D and Calcium Therapy: how much is enough

Vitamin D and Calcium Therapy: how much is enough Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

The Endocrine Society Guidelines

The Endocrine Society Guidelines Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS

More information

Hypertension Management: A Moving Target

Hypertension Management: A Moving Target 9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,

More information

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline

More information

Vitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016

Vitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016 Vitamin D: What s New and Not? Clifford J Rosen MD Maine Medical Center Research Institute rosenc@mmc.org Conflict of Interest Statement Corporate NO STOCKS or EQUITY Editor UpToDate, New England Journal

More information

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode

More information

Clinical Care Performance. Financial Year 2012 to 2018

Clinical Care Performance. Financial Year 2012 to 2018 Clinical Care Performance Financial Year 2012 to 2018 SHP Clinical Care Performance Diabetes Mellitus Hyperlipidemia Hypertension Diabetes Mellitus Find out how our patients are doing for: HbA1C HbA1c

More information

Blood Pressure LIMBO How Low To Go?

Blood Pressure LIMBO How Low To Go? Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Alpha blockers have no role in renal colic

Alpha blockers have no role in renal colic Alpha blockers have no role in renal colic HARRY WINKLER Director, section of Endourology Kidney stone center Dept.of Urology Sheba Medical Center Financial and Other Disclosures Off-label use of drugs,

More information

Dyslipidemia in women: Who should be treated and how?

Dyslipidemia in women: Who should be treated and how? Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European

More information

Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)

Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3) Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3) Χάρης Γράσσος MD,FESC,PhD,EHS Διευθυντής Καρδιολόγος Γ.Ν.Α ΚΑΤ Visiting Professor University of Bolton U.K New England

More information

PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC

PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Chronic Disease Management when Resources are Limited

Chronic Disease Management when Resources are Limited Chronic Disease Management when Resources are Limited Paul R. Larson MD, MS, DIM&PH Director, Global Health Education UPMC St. Margaret Family Medicine Residency Pittsburgh, PA larsonpr@upmc.edu Disclosures

More information

Update in Pulmonology Update in Medicine and Primary Care November 11, 2017

Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program

More information

The ABCs (A1C, BP and Cholesterol) of Diabetes

The ABCs (A1C, BP and Cholesterol) of Diabetes The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal

More information

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,

More information

Blood Pressure Measurement in SPRINT

Blood Pressure Measurement in SPRINT Blood Pressure Measurement in SPRINT Karen C. Johnson, MD, MPH, FAHA Vice Chair, SPRINT Steering Committee University of Tennessee Health Science Center, Department of Preventive Medicine For the SPRINT

More information

NEWS & VIEWS. Hole in the diet-heart hypothesis?

NEWS & VIEWS. Hole in the diet-heart hypothesis? NEWS & VIEWS Hole in the diet-heart hypothesis? Philip C. Calder Faculty of Medicine, University of Southampton, MP887 Southampton General Hospital, Tremona Road, Southampton SO16 6YD, United Kingdom and

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Good hydration checklist

Good hydration checklist Good hydration checklist Staying hydrated is very important because our bodies need the right balance of water and electrolytes to help them function properly. Drink the right amount and types of fluid

More information

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between

More information

Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People

Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People For the Motion: Professor Roger Francis, Institute for Ageing and Health, Newcastle University,

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information